
Fulcrum Therapeutics, Inc.: updates and filings
Price
$3.69
November 20, 2026Market cap $282M
What Ploutos Investor adds for Fulcrum Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
June 2026
April 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 12, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 12, 2026FilingForm425
- Nov 12, 2026Other material eventsForm8-K
- Nov 4, 2026FilingFormEFFECT
- Nov 3, 2026Filing (amendment)FormS-4/A
- Oct 28, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 20, 2026Filing (amendment)FormS-4/A
- Oct 8, 2026Filing (amendment)FormS-4/A
- Sep 2, 2026FilingFormS-4
- Aug 17, 2026FilingForm425
- Aug 17, 2026FilingForm425
- Aug 17, 2026FilingForm425
- Aug 17, 2026Material agreement entered, unregistered sale of shares, change in control, officer or director change, Regulation FD disclosureForm8-K
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 14, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 10, 2026Officer or director changeForm8-K
- Aug 3, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jul 30, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 12, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 12, 2026 | 425 | Filing | Document |
| Nov 12, 2026 | 8-K | Other material events | Document |
| Nov 4, 2026 | EFFECT | Filing | Document |
| Nov 3, 2026 | S-4/A | Filing (amendment) | Document |
| Oct 28, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 20, 2026 | S-4/A | Filing (amendment) | Document |
| Oct 8, 2026 | S-4/A | Filing (amendment) | Document |
| Sep 2, 2026 | S-4 | Filing | Document |
| Aug 17, 2026 | 425 | Filing | Document |
| Aug 17, 2026 | 425 | Filing | Document |
| Aug 17, 2026 | 425 | Filing | Document |
| Aug 17, 2026 | 8-K | Material agreement entered, unregistered sale of shares, change in control, officer or director change, Regulation FD disclosure | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 14, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 10, 2026 | 8-K | Officer or director change | Document |
| Aug 3, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jul 30, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jul 25, 2016.
The full analysis
What do Fulcrum Therapeutics's filings show?
The filings are where every one of Fulcrum Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.